Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.

Aims: To compare insulin and glucose profiles during basal continuous subcutaneous infusion of a rapid-acting insulin analogue and once daily subcutaneous injection of a long-acting insulin analogue in Type 2 diabetes.

Methods: Twenty-one patients with Type 2 diabetes treated with oral glucose-lowering agents were randomized in this two-period crossover study to an equivalent 24-h dose of continuous subcutaneous infusion of insulin aspart and subsequently once-daily bedtime subcutaneous injection of insulin glargine, or vice versa, for eight consecutive days. Plasma profiles of insulin and glucose were recorded.

Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral antidiabetic drugs in type 2 diabetes.

Background: Basal continuous subcutaneous insulin infusion (CSII) therapy at a fixed rate may effectively improve glycemic control in patients with type 2 diabetes when oral antidiabetic treatment fails. Regimens of simple constant subcutaneous delivery of insulin may provide theoretical advantages in type 2 diabetes.

Methods: Ten subjects with type 2 diabetes who obtained insufficient glycemic control on oral antidiabetic drugs were included.

Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.

Aim: To evaluate the potential advantages of a constant overnight subcutaneous delivery of insulin in type 2 diabetic patients who fail to achieve glycaemic control on oral antidiabetics.

Methods: Ten type 2 diabetic patients treated with oral antidiabetic drugs without gaining sufficient glycaemic control were included in this three-period study. All patients received continuous subcutaneous insulin infusion (CSII) with a short-acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period A).

InDuo, a novel combined insulin injection and blood glucose monitoring device - effective and save as other devices, and patient preference.

Background And Aim: Frequent blood glucose (BG) monitoring and insulin administration are necessary in intensive insulin regimes. A new integrated system, InDuo is a compact and portable combined insulin doser and BG monitor, designed to overcome some of the limitations of current insulin therapy. The aim of the study was to compare InDuo and a non-integrated system (HumaPen Ergo and Accu-Chek Sensor Meter) for efficacy and safety, and to evaluate patients preference.

The effects of skin temperature and testing site on blood glucose measurements taken by a modern blood glucose monitoring device.

Background: Modern blood glucose (BG) monitoring devices (e.g., InDuo [LifeScan, Inc.

A comparison of colour micrographs obtained with a charged couple device (CCD) camera and a 35-mm camera.

Purpose: The purpose of this study was to determine if micrographs produced with a colour charged couple device (CCD) camera were comparable in quality to micrographs obtained with a 35-mm colour film camera. The Axiocam (Zeiss, Jena, Germany) CCD camera produced images of 3900 x 3090 pixels.

Methods: Each picture in a series of 50 pairs of film and digital micrographs was rated independently by each of three observers on the categories of colour, detail and overall impression.

Patient perception and use of an insulin injector/glucose monitor combined device.

Purpose: This clinical trial assessed patient preference, satisfaction, and use of an insulin injector/glucose monitor combination device versus syringes and a separate glucose monitor.

Methods: In a randomized, multicenter, 2-period crossover study, 15 patients with type 1 diabetes were randomized to use either a combined injector/monitor device or syringes, a vial, and a separate glucose monitor, then switched to the alternate treatment. Efficacy, safety, preference, satisfaction, and actual use (via meter download) of the 2 systems were compared.